APA (7th ed.) Citation

Heerspink, H. J. L., Jardine, M. J., Kohan, D. E., Lafayette, R., Levin, A., Liew, A., . . . Dahlke, M. (2026). Atrasentan in patients with IgA nephropathy (ALIGN): Final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 407(10546), 2387. https://doi.org/10.1016/S0140-6736(26)00960-8

Chicago Style (17th ed.) Citation

Heerspink, Hiddo J L., et al. "Atrasentan in Patients with IgA Nephropathy (ALIGN): Final 2·5-year Results from a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." Lancet 407, no. 10546 (2026): 2387. https://doi.org/10.1016/S0140-6736(26)00960-8.

MLA (9th ed.) Citation

Heerspink, Hiddo J L., et al. "Atrasentan in Patients with IgA Nephropathy (ALIGN): Final 2·5-year Results from a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." Lancet, vol. 407, no. 10546, 2026, p. 2387, https://doi.org/10.1016/S0140-6736(26)00960-8.